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Abstract 
This systematic review aims to assess the efficacy of light therapy on behavioural and psychological 
symptoms of dementia (BPSD), cognition, functional status, and quality of life in older adults with cognitive 
impairment; and secondarily, to identify the optimal characteristics of light therapy to establish an adequate 
protocol for its clinical application. We searched Web of Science and Medline databases through December 
2019, resulting in 36 included articles: 3 evaluated the effects on BPSD, 25 on sleep, 12 on agitation, 10 on 
mood, 4 on neuropsychiatric symptoms, 4 on cognition, 2 on quality of life and 2 on functional status. 
Literature has shown potential evidence for positive effects of light therapy on managing sleep, behavioural 
and mood disturbances in people with cognitive impairment, but a limited effect on cognition, quality of life 
and functional status. This review provides guidelines for intervention protocols with light therapy in older 
people with cognitive impairment. 
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Introduction 
The number of people affected by dementia worldwide is 50 million and will continue to 
increase dramatically in the next decades, representing one of the most important public health 
problems.1 It is the main reason for the functional dependence and institutionalization of older 
adults, with a high economic impact on society.2 
 
Dementia affects cognitive function and is usually accompanied by the presence of behavioural 
and psychological symptoms of dementia, BPSD,3 which comprise four factors: a psychosis 
factor- irritability, agitation, hallucinations, and anxiety; a psychomotor factor- aberrant motor 
behaviour and delusions; a mood liability factor- disinhibition, elation and depression; and an 
instinctual factor- appetite disorders, sleep disorders and apathy.4 The most prevalent BPSD are 
apathy, depression, irritability, agitation, and anxiety, while the less prevalent ones are euphoria, 
hallucinations, and disinhibition.5 It is important to note that the prevalence of BPSD may vary in 
each subtype of dementia (see a review5), patients with vascular dementia have reported a higher 
prevalence and severity of depression and anxiety, or patients with dementia with Lewy bodies a 
higher prevalence of delusions and hallucinations, in comparison to Alzheimer's Disease, with a 
higher prevalence of aberrant motor behaviour. 
 
BPSD are the most distressing symptoms of dementia for caregivers and contribute to 
institutionalization,6 with agitation being one of the most relevant symptoms, affecting both formal 
and informal caregivers.7 Sleep disturbances also represent an important clinical problem in 
dementia and are the main contributor to caregiver distress.8 
 
Accurate BPSD characterization and intervention are key factors in the treatment of dementia, 
including a combination of pharmacological and non-pharmacological interventions.5 BPSD 
management is a very difficult task for formal and informal caregivers due to possible adverse 
events or a lack of research supporting the use of different interventions.3 Pharmacological and 
non-pharmacological interventions have been proposed for the treatment of both BPSD and 
cognitive impairment, and although the former (mainly antipsychotics) have demonstrated a 
slightly larger effect size, non-pharmacological strategies should be initially recommended to 
manage dementia (see a review9). In fact, the American Geriatrics Society Beers Criteria Update 
Expert Panel10 recommends, “antipsychotics must be avoided for BPSD unless 
nonpharmacological options have failed or are not possible and the older adult is threatening 
substantial harm to self or others”. Therefore, alternative interventions are being used as a non-
pharmacological approach to symptoms associated with dementia due to the lack of adverse events 
(see reviews9,11 such as individualized music,12 multisensory stimulation,13 aromatherapy,14 
reminiscence therapy,15 and light therapy16,17). 
 
Light therapy offers a promising non-pharmacological alternative in people with dementia to 
treat the physiological changes associated with alterations of circadian rhythm.18 Older adults with 
dementia have a decreased general sensory input, low sensitivity to the light effect on the 
suprachiasmatic nucleus (SCN) and less exposure to bright environmental light.18 Light therapy 
might reverse the degenerative changes in the SCN, which are the biological basis for circadian 
(rest-activity and sleep-wake cycles) disturbances in people with dementia.18 Most institutional 
settings maintain consistent low light levels, which may not be sufficient to enable the circadian 
clock to entrain to the 24-hour day.19 There is evidence that effective light doses would stimulate 
the circadian cycles, affecting sleep efficiency (see a review20), depression,21 functional status22 or 
behavioural problems23,24 in older adults with dementia. Light therapy involves exposure under 
controlled conditions to certain levels of light. There are different forms of administering light 
therapy, using outdoor sunlight or artificial indoor light sources. Different light sources or devices 
can provide it: light boxes placed approximately one meter away from the subjects at a height 
within their visual fields; a light visor worn on their heads; or a more acceptable ’naturalistic’ light 
therapy, known as a dawn-dusk simulation that mimics outdoor twilight transitions.25 In all cases, 
light needs to enter the user's eyes to be effective, however it is not necessary to stare at the light 
source, even looking at lights is not recommended with some devices.26 People may do other 
activities while receiving the light stimulation in their visual field, such as eating, watching 
television or reading, being easily implementable either in institutions or in dwellings. 
Additionally, there is wide methodological heterogeneity with regard to the light intensity, 
frequency, interval, time of the day, and length of the intervention among the studies.18 
 
Importantly, limited research has been conducted to examine the efficacy of light therapy in 
managing BPSD in older adults with cognitive impairment. In fact, in the most recent review17 
examining light therapy, the authors did only involve participants with Alzheimer's disease. 
Therefore, this systematic review differs from others in providing an overview of the existing 
literature to date that examine the effect of light on BPSD, cognition, functional status, and quality 
of life in participants with all degrees of cognitive impairment. Moreover, this review pursues to 
provide a more practical point of view in order to facilitate the implementation of light therapy 
protocols in daily clinical practice. 
 
The aim of the present systematic review is to assess studies exploring the efficacy of light 
therapy as a non-pharmacological approach to manage BPSD, as well as its effectiveness in 
cognition, functional status, and quality of life in people with cognitive impairment (not 
necessarily with a diagnosis of dementia). Additionally, we aim to identify the light therapy 
conditions with the highest efficacy for older adults with cognitive impairment in order to facilitate 
the establishment of an adequate protocol for the clinical application of light therapy in this 
population. 
 
Materials and methods 
The Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 
guidelines were used for reporting of this systematic review.27 
 
Search strategy 
We identified articles that assessed the effect of light therapy for older adults with cognitive 
impairment by searching the Web of Science and Medline databases. The search included articles 
published until December 2019. Search terms included (“light therapy” or “light treatment” or 
“light exposure” or “bright light” or “effect of light”), and (“elder*” or “old*” or “dement*” or 
“Alzheimer” or “nursing home” or “day care”). Combinations of these terms were used for the title 
search (see search strategy in Appendix A published as supplementary material online). All 
possible articles were merged into a single file, and duplicate records were removed after they 
were checked manually. Two of the investigators independently evaluated the appropriateness of 
inclusion, and discrepancies were discussed and solved to reach a consensus. If disagreements 
arose, a third investigator was included in the discussion to reach the final consensus. 
 
Study selection 
The following inclusion criteria were established to select articles for this systematic review. 
Regarding participants: individuals with a mean age of 65 years or older with cognitive 
impairment (mild cognitive impairment and mild, moderate or severe dementia). In terms of the 
intervention: any type of light therapies, with specific information about duration and frequency. 
As regards the outcome measures: the effect on BPSD (especially with regard to sleep and 
agitation), cognitive status, functional status or quality of life as the primary outcome. Finally, 
with regard to language: only full-text articles written in English or Spanish were eligible. As 
exclusion criteria: reviews, letters, editorials, conference abstracts or papers, corrections or book 
chapters were excluded. 
 
Quality assessment and data extraction 
This systematic review adheres to the guidelines detailed on the PRISMA protocol.27 The 
quality of the selected papers was assessed by two independent researchers, using two Critical 
Appraisal Tools provided by the Joanna Briggs Institute (JBI) ,28 with a third investigator in case 
of any disagreements, likewise done for the included studies. JBI Critical Appraisal Checklist for 
Randomized Controlled Trials, with 13 items, was used to assess 18 articles. The other 18 articles 
were evaluated by JBI Critical Appraisal Checklist for Quasi-Experimental Studies (non-
randomized experimental studies), with 9 items. At the end of the quality assessment of each 
article, an overall score of appraisal is determined based on the criteria number ranked as “Yes”. 
 
Data of each article included were collected according to the following characteristics: authors 
and year of publication, study design and intervention setting (gerontological complex, 
community-dwelling, hospital…), sample characteristics (age and sex), cognitive status, 
intervention characteristics (intensity, frequency, and duration), assessed outcomes, measurement 
tools, and main findings. 
 
This systematic review did not require ethics approval from an ethics committee. 
 
Due to the heterogeneity of the results, the measures and the design, a meta-analysis was not 
appropriate in this case. 
 
Results 
Fig. 1 includes the PRISMA flow chart of the study selection process. The search of Web of 
Science produced 208 results and of Medline produced 152 results. Moreover, 4 additional records 
were identified through the bibliography of some of the analysed articles. Of the 246 studies 
identified after removing duplicates, 101 remained as potentially relevant and were analysed in 
terms of their eligibility. Of these studies, 35 were excluded for the setting, 5 for not being focused 
on BPSD, cognitive status or quality of life, 9 for insufficient reporting of light therapy and 16 for 
not being original research (see Appendix B published as supplementary material online). Finally, 





Fig 1. PRISMA Flow Diagram of literature search and selection process of the current systematic review. 
Table 1 summarizes the characteristics of the included studies. As can be seen in the table, 
multiple articles, based on the same study sample, but describing different outcomes, were 
included in this systematic review. 
Table 1. Characteristics of the included studies in the systematic review. 
Author (year) Study design/ 
Setting 









n = 77 (58 women) 
Mean age = 85. 
7 ± 7. 3 
Mean MMSE = 12. 8 ± 8. 8 
(range = 0–30) 
Four conditions: EBL, MBL, 
daytime sleep restriction, 
DRL. 
Procedure: BL (2500 lux), 




Actigraphy No improvements in night-time sleep or daytime 
alertness. Morning bright light: a delayed peak of 
the activity rhythm, increased mean activity level 





n = 92 (63 women) 
Mean age = 82. 
3 ± 7. 6 
Probable or possible AD, 
mean MMSE = 5. 7 ± 5. 6 
(range = 0–22) 
Three conditions: MBL, 
morning DRL, EBL. 
Procedure: BL (2500 lux), 
DRL (<300 lux); 10 d; 2 h/d 
Agitation CMAI, ABRS CMAI: significant improvement in physical, 
verbal and overall agitation caregiver ratings of 






n = 92 (63 women) 
Mean age = 82. 
3 ± 7. 6 
Probable or possible AD, 
mean MMSE = 5. 7 ± 5. 6 
(range = 0–22) 
Three conditions: MBL, 
morning DRL, EBL. 
Procedure: BL (2500 lux), 
DRL (<300 lux); 10 d; 2 h/d 
Sleep Actigraphy Increased MBL or EBL consolidates night-time 
sleep by lengthening the maximum sleep bouts 
during the night. Time asleep did not vary as there 








n = 66 (31 women) 
Mean age = 79 
Dementia, MDS-
COGS/MMSE: Mild: n = 3; 
Moderate: n = 18; 
Severe: n = 31; Very 
severe: n = 14 
Four conditions: MBL, EBL; 
all day BL, STL. 
Procedure: BL (2000–
3000 lux), STL (500–
600 lux); 3 weeks; MBL EBL: 
4 h/d, all day BL: 13 h/d 
Agitation CMAI BL was not effective in reducing agitation under 





n = 48 (32 women) 
Mean 
age = 83,5 ± 1,6 
Dementia diagnosis, mean 
MMSE: STL group = 5. 
1 ± 5. 6; BL group = 6. 
9 ± 5. 3 
Two conditions: MBL and 
STL. 
Procedure: MBL (10,000 lux), 









Limited evidence of a reduction in agitation. Sleep 
and diurnal rhythm are improved, suggesting 





n = 46 (36 women) 
Mean age = 84. 
0 ± 10. 0 
AD diagnosis, mean 
MMSE = 6. 7 ± 6. 8 
Two conditions: MBL and 
STL. 
Procedure: MBL (≥2500 lux), 
STL (150–200 lux); 10 weeks; 
1 h/d 
Sleep Actigraphy Significant improvement in rest-activity rhythms 


































Author (year) Study design/ 
Setting 









n = 70 (57 women) 
Mean age = 84. 
0 ± 10. 0 
AD diagnosis, mean 
MMSE = 7. 0 ± 7. 0 
Three conditions: MBL, EBL, 
STL. 
Procedure: BL (≥2500 lux), 
STL (150–200 lux); 10 weeks; 
1 h/d 
Sleep Actigraphy No significant differences in night-time sleep or 
day-time wakefulness. MBL implies a 





n = 70 (57 women) 
Mean age = 84. 
0 ± 10. 0 
AD diagnosis, mean 
MMSE = 7. 0 ± 7. 0 
Three conditions: MBL, EBL, 
STL. 
Procedure: BL (≥2500 lux), 
STL (150–200 lux); 10 weeks; 
1 h/d 
NPS NPI – NH Significant differences in depression/dysphoria, 
aberrant motor behaviour, and eating disorders, 






n = 50 (43 women) 
Mean age = 86. 
0 ± 8. 0 
AD diagnosis, mean 
MMSE = 9. 3 ± 7. 9 
Three conditions: 
MBL + melatonin, 
MBL + placebo, STL. 
Procedure: MBL (≥2500 lux), 
STL (150–200 lux); 10 weeks; 
1 h/d 
Sleep Actigraphy MBL plus melatonin significantly improves day-
time somnolence, reduces the duration of day-time 
sleep, increases day-time activity, and improves 






n = 11 (10 women) 
Mean age = 86. 
1 ± 8. 9 
Moderate to severe 
dementia, mean 
MMSE = 11. 7 ± 4. 2; Mean 
CDR = 2. 5 ± 0. 5 
One condition: MBL. 
Procedure: 6000–8000 lux; 2 
weeks; 2 h/d 




Significant improvements in nocturnal sleep, sleep 






n = 11 (10 women) 
Mean age = 86. 
1 ± 8. 9 
Moderate to severe 
dementia, mean 
MMSE = 11. 7 ± 4. 2; Mean 
CDR = 2. 5 ± 0. 5 
One condition: MBL. 
Procedure: 6000–8000 lux; 2 
weeks; 2 h/d 
Sleep Actigraphy Significant positive effects on sleep disturbances 
(sleep onset latency, nocturnal wake time and 






n = 11 (10 women) 
Mean age = 86. 
1 ± 8. 9 
Moderate to severe 
dementia, mean 
MMSE = 11. 7 ± 4. 2; Mean 
CDR = 2. 5 ± 0. 5 
One condition: MBL. 
Procedure: 6000–8000 lux; 2 
weeks; 2 h/d 




Significant positive effect on daytime 






n = 14 (9 women) 
Mean age = 86. 
9 ± 4. 4 
Mild-moderate dementia, 
mean BIMS = 7. 7 ± 2. 3 
One condition: Bluish-white 
light. 
Procedure: 324±190 lux; 4 











Significant increase in total sleep time and sleep 
efficiency. Significant improvement in sleep, 
depression and agitation scores from the 
standardized questionnaires applied 
Author (year) Study design/ 
Setting 











 = 35 (9 women) and 
34 caregivers (27 
women) 
Mean age = 80. 
8 ± 7. 9 
Mild-moderate dementia, 
MMSE = range 12–24; 
CDR = range 1–2 
One condition: Bluish-white 
light. 
Procedure: 350–400 lux; 4 









Significant increase in circadian entrainment in 
both, participants with dementia and their 
caregivers. Participants with dementia also 







n = 13 (12 women) 
Mean 
age = 84,9 ± 4,8 
Diagnosis of dementia, 
mean MMSE: DDS 
group = 13. 8 ± 5. 9; 
placebo group = 14. 3 ± 4. 1 
Two conditions: DDS and 
placebo (DRL). 
Procedure: DDS (max. 
400 lux), DRL (<5 lux); 3 
weeks; per day: dawn time 










DDS group presented shortened sleep latency, 
longer sleep duration, more nocturnal immobility 
and less nocturnal activity than the DRL group. 








n = 54 (23 women) 
Mean age = 77. 
9 ± 8. 1 
Mild cognitive impairment 
to dementia, mean 
MMSE = 22. 1 ± 4. 7; 
CERAD = 1. 3 ± 1. 8 
Two conditions: MBL and 
DRL 
Procedure: MBL 
(4200±1600 lux), DRL 
(90±96 lux); 2 weeks; 
30 min/d 
Sleep Actigraphy, ESS, 
Daily sleep 
reports 
30-min MBL is not sufficient for improving sleep 
Graf (2001)34 Parallel group 
design 
Nursing home 
n = 23 
Mean age = 82. 
1 ± 6. 4 
AD or VD, mean MMSE: 
MBL group = 15. 2 ± 4. 8; 
MDL group = 17. 1 ± 7. 1 
Two conditions: MBL and 
MDL. 
Procedure: MBL (3000 lux), 
MDL (100 lux); 10 d; 2 h/d 






n = 10 (7 women) 
Mean age = 72. 1 
Dementia diagnosis Two conditions: 
MBL + melatonin and 
MBL + placebo. 
Procedure: 10,000 lux; 2 
periods of 2 weeks; 30 min/d 
Agitation CGI, GIP, SDAS Positive effects for the MBL combined with 
placebo. Patients were less restless and more co-
operative. The condition with melatonin showed 








n = 66 (31 women) 
Mean age = 79 
Dementia, MDS-COGS/ 
MMSE: Mild to 
moderate: n = 21; 
severe: n = 31; and very 
severe: n = 14 
Four conditions: MBL, EBL, 
all day BL, STL. 
Procedure: BL (2000–
3000 lux), STL (500–
600 lux); 3 weeks; MBL and 
EBL: 4 h/d, all day BL: 13 h/d 
Mood CSDD MBL significantly decreases depressive 
symptoms in some people but may worsen 
symptoms in others. Individual more than unit-


















Author (year) Study design/ 
Setting 









n = 6 (5 women) 
Mean age = 89. 
2 ± 3. 4 
Moderate to severe 
dementia, mean MMSE = 8. 
7 ± 5. 2 
One condition: MBL. 
Procedure: 2500 lux; two 10 d 
MBL periods; 2 h/d 









n = 15 (14 women) 
Mean age = 80. 
8 ± 8. 7 
 
Dementia, mean 
MMSE = 6. 4 ± 6. 8 
 
Two conditions: MBL and 
STL. 
Procedure: MBL (10,000 lux); 









No effect on agitation or depression. Significant 






n = 132 (73 
women) 
Mean age = 81. 
0 ± 8. 0 
Probable or possible AD 
diagnosis, mean 
MMSE = 18. 7 ± 6. 9 
Four conditions: 1-walking, 2-
EBL, 3-
walking + light + sleep 
education, 4-control. 
Procedure: EBL (2500 lux); 8 
weeks; 1 h/d 
Sleep Actigraphy, SDI Light therapy and walking, singly or in 
combination, significantly improve night-time 







n = 24 
Mean age = 75 
Moderate and severe 
dementia, VD or AD 
diagnosis 
Two conditions: MBL and 
control. 
Procedure: 3000–5000 lux; 4 
weeks; 2 h/d 
Sleep, BPSD Sleep diary by 
nursing staff 
Significant increase in total and nocturnal sleep 
time and a significant decrease in daytime sleep 
time. The presence of behaviour disorders during 
the intervention period was significantly lower 





n = 22 (9 women) 
Mean age = 79. 5 
VD or AD diagnosis, mean 
MMSE: VD group = 8. 0 
(range 3 – 14); AD 
group = 9. 0 (range 3–17) 
Two conditions: MBL and 
MDL. 
Procedure: MBL (5000–
8000 lux), MDL (300 lux); 4 
weeks; 2 h/d 
Sleep Actigraphy Significant improvement of MBL in nocturnal 







n = 89 (58 women) 
Mean age = 78. 
4 ± 9. 0 
Severe cognitive 
impairment, mean S-
MMSE = 8. 8 ± 10. 2 
Two conditions: Low and high 
light. 
Procedure: Low (<417. 
24 lux), high (>417. 24 lux);8 











Higher light exposure results in an increase in 
positive emotions, greater general alertness and 





n = 60 (43 women) 
Mean age = 82. 
6 ± 9. 6 
Dementia diagnosis, 
Mild: n = 7; 
Moderate: n = 11; 
Severe: n = 42. ; mean 
MMSE = 7. 2 ± 6. 9 
Two conditions: MBL+EBL 
and STL. 
Procedure: BL (10,000 lux), 
STL (250 lux); 8 weeks; 








Significant improvement in all three measures of 
depression and all four measures of agitation 
Author (year) Study design/ 
Setting 











n = 60 (43 women) 
Mean age = 82. 
6 ± 9. 6 
Dementia diagnosis, 
Mild/moderate: n = 18; 
Severe: n = 42; mean 
MMSE = 7. 2 ± 6. 9 
Two conditions: MBL+EBL 
and STL. 
Procedure: BL (10,000 lux), 
STL (250 lux); 8 weeks; 
30 min twice a day; 5 d/week 
Mood DSAOA, CSDD 
(Analysis of the 
total scores and 
their individual 
subscales) 
Total scores: equally effective at mild/moderate 
and severe stages of dementia. Subscales: greater 
benefits for severe dementia than mild/moderate 
in two DSAOA subscales (disagreeable behaviour 
and sleep impairment) 
Riemersma-





n = 189 (170 
woman) 
Mean age = 85. 
5 ± 5. 5 
Dementia diagnosis, mean 
MMSE = 16. 4 ± 5. 6 
Four conditions: 1-BL, 2-
Melatonin, 3-BL + Melatonin, 
4-DL. 
Procedure: BL (±1000 lux), 
DL (±300 lux); 15±12 












BL ameliorated cognition and depressive 
symptoms and also attenuated the increase in 
functional limitations over time. Melatonin + LB 
improved agitation, nocturnal restlessness, sleep 






n = 10 (1 woman) 
Mean age = 70. 
1 ± 5. 1 
Moderate to severe 
dementia, mean MMSE = 0. 
6 ± 1. 1 
One condition: MBL. 
Procedure: 1500–2000 lux; 2 
weeks; 2 h/d 
Agitation, 
Sleep 
Daily ratings by 
nursing staff 
Improvements in sleep-wakefulness, nocturnal 
activity decreased and the relative amplitude of 






n = 5 (4 women) 
Mean age = 81. 
8 ± 6. 3 
Dementia diagnosis One condition: MBL 
Procedure: 2500 lux; 2 weeks; 
2 h/d 
NPS CRS Delusions slightly improved in three of the 
participants, another did not show them neither 






n = 17 (6 women) 
Mean age = 75. 
5 ± 6. 2 
Dementia diagnosis, mean 
MMSE = 12. 1 ± 8. 2 
One condition: MBL. 
Procedure: 5000 lux; 2 weeks; 
1 h/d 
Sleep NPI-NH (Sleep 
disturbances) 
Improvement of sleep disturbance in four AD 






n = 10 (3 women) 
Mean age = 79. 4 
VD or AD diagnosis, 
Median MMSE = 0 
(range = 0–11) 
One condition: MBL. 
Procedure: 5000–8000 lux; 4 
weeks; 45 min/d 
BPSD, Sleep CMAI, 
BEHAVE-AD, 




Significant reduction of BPSD. No effect on 
sleep-wake measures but an improvement of 








n = 66 (31 women) 
Mean age = 79 
Dementia, MDS-COGS/ 
MMSE: Mild to 
moderate: n = 21; 
severe: n = 31; and very 
severe: n = 14 
Four conditions: MBL, EBL, 
all day BL, STL. 
Procedure: BL (2000–
3000 lux), STL (500–
600 lux); 3 weeks; MBL and 




Actigraphy Night-time sleep increased significantly in 
participants exposed to morning and all-day light, 
with the increase most prominent in participants 
with severe or very severe dementia 
Author (year) Study design/ 
Setting 










n = 17 (11 
women); 
Age: 65–79 = 6; 
≥80 = 11 
Dementia diagnosis; mean 
MMSE = 12. 7 ± 9. 1 
Two conditions: BWL and 
RYL. 
Procedure: BWL (300–
400 lux), RYL 
(mean = 118 lux); 6 weeks; 










No significant evidence of sleep improvement or 
other outcomes in people with dementia. For 






Long term care 
facility 
n = 16 (13 women) 
Mean age = 80. 3 
Dementia diagnosis; mean 
GDS = 6 (range 5–7) 
One condition: MBL. 
Procedure: 10,000 lux; 1 




CMAI, EBIC CMAI: a significant decrease in agitation during 
MBL compared with the post-therapy week. 
EBIC: MBL showed a trend to increase positive 







n = 22 (15 women) 
Mean age = 79±2 
Dementia diagnosis; mean 
GDS = 6. 3 ± 0. 13 (range 
5–7) 
Two condition: BL and 
baseline. 
Procedure: BL 
(mean = 1136±89 lux), 
baseline (mean = 436±90 or 
372±89 lux); 4 weeks; all-day 
Circadian 
rhythm 
Actigraphy BL improves the circadian rest-activity rhythm 
disturbances in severely demented patients with 
intact vision, but not in those with visual 
impairment 
Note. *, †, ‡, §, ¶: Articles with the same symbol report data from the same study sample but describe different outcomes. Abbreviations: ABA: baseline with no treatment (A) and treatment (B); 
ABABA: Alternating baseline (A) and treatment (B) conditions; ABRS: Agitated Behaviour Rating Scale; AD: Alzheimer's Disease; ADL: Activities of Daily Living; BARS: Brief Agitation Rating 
Scale; BEHAVE-AD: The Behavioural pathology in Alzheimer's Disease; BIMS: Brief Interview for Mental Status; BL: Bright Light; BPSD: Behavioural and Psychological Symptoms of Dementia; 
BWL: Blue-White Light; CADS: Change in Advanced Dementia Score; CDR: Clinical Dementia Rating; CERAD: Consortium to Establish a Registry for Alzheimer's Disease; CGI: Clinical Global 
Impression; CMAI: Cohen-Mansfield Agitation Inventory; CMAI-D: Cohen-Mansfield Agitation Inventory-Disruptiveness; CMAI-F: Cohen-Mansfield Agitation Inventory-Frequency; CRBRS: 
Crichton Royal Behaviour Rating Scale; CRS: Confusion Rating Scale; CSDD: Cornell Scale for Depression in Dementia; DDS: Dawn-Dusk Simulation; DL: Dim light; DMAS-17: Dementia Mood 
Assessment Scale-17 item; DRL: Dim Red Light; DSAOA: Depressive Symptom Assessment in Older Adults; EBIC: Environment-Behaviour Interaction Code; EBL: Evening Bright Light; ESS: 
Epworth Sleepiness Scale; GDS: Global Deterioration Scale; GDS-SF: Geriatric Depression Scale – Short Form; GIP: Gedragsobservatieschaal voor Intramurale Psychogeriatrie; MBL: Morning 
Bright Light; MD: Mixed Dementia; MDL: Morning Dim Light; MDS-ADL: Minimum Data Set – Activities of Daily Living Scale; MDS-COGS: Minimum Data Set - Cognition Scale; MMSE: Mini- 
Mental State Examination; MOS: Medical Outcomes Study sleep scale; MOSES: Multi Observation Scale for Elderly Subjects; MOUSEPAD: Manchester and Oxford Universities Scale for the 
Psychopathological Assessment of Dementia; NI-ADL: Nurse-informant activities of daily living scale; NPI-NH: Neuropsychiatric Inventory Nursing Home Version; NPS: Neuropsychiatric 
Symptoms; OERS: Observed Emotion Rating Scale; PAS: Pittsburgh Agitation Scale; NPI-Q: Questionnaire format of Neuropsychiatric Inventory; PGCARS: Philadelphia Geriatric Centre Affect 
Rating Scale; PGCMS: Philadelphia Geriatric Centre Morale Scale; PHQ-9: Patient Health Questionnaire; PSQI: Pittsburgh Sleep Quality Index; QoL: Quality of Life; QOL_AD: Quality of Life in 
Alzheimer's Disease; QUALID: Quality of Life for Severe Dementia; RCT: Randomized Controlled Trial; RYL: Red-Yellow Light; SDAS: Social Dysfunction and Aggression Scale; SDI: Sleep 
Disorders Inventory; S-MMSE: Severe Mini- Mental State Examination; STL: Standard Light; VD: Vascular Dementia. 
 
In this systematic review, the mean sample size was 42.5 ± 42.5 in 29 studies (36 articles), with 
a minimum of 5 individuals29 and a maximum of 189.30 For all studies included in the analysis, the 
total sample size was 1233 older adults (66.1% women). Only nine articles contained a greater 
number of men than women.31, 32, 33, 34, 35, 36, 37, 38, 39 The mean age of the included participants was 
81.3 ± 4.5 years, ranging from 70.1 ± 5.137 to 89.2 ± 3.4 years.24 Most of the articles assessed the 
effect of light therapy in older adults within the residential/nursing home setting, excluding three 
that also combined participants from hospitals,31,40,41 seven that only involved a hospital 
setting29,35, 36, 37, 38,42,43 and four that included community-dwelling older adults.32,33,44,45 Twenty of 
the articles identified in the search were from the USA, 4 from Norway,39,46, 47, 48 three from 
Japan,35,36,38 three from the Netherlands,30,42,43 two from Austria,29,34 two from Switzerland,49,50 one 
from the United Kingdom,51 and one from Canada.52 
 
The results are grouped into six subsections: the first one includes the methodological quality 
assessment of included articles. The following 4 subsections present the main outcomes (light 
therapy and BPSD, light therapy and cognition, light therapy and quality of life, and light therapy 
and activities of daily living) described in Table 1. As observed, three of the articles examined the 
effect of light treatment on BPSD as a whole, regarding effects on specific BPSD: 25 of the 
articles examined the effect of light on sleep, 12 on agitation, 10 on mood and 4 on 
neuropsychiatric symptoms. Additionally, four articles assessed the effect on cognition, two on 
quality of life and two on functioning in activities of daily living. A final sixth subsection was 




Regarding quality assessment, studies were analysed using the corresponding form of JBI 
appraisal tool according to the type of design used in each article: checklist for Randomized 
Controlled Trials - RCT (Table 2) and checklist for Quasi-Experimental Studies - QES (Table 3). 
In Table 2, only three30,44,53 of the 18 included studies met 10 or more (80%) of the 13 criteria on 
the JBI for RCT. A lack of quality was observed in most of the 18 studies, 10 (55.6%) of 
them19,33,34,45,49,54, 55, 56, 57, 58 had equal or below six scores (less than half of the defined appraisal 
criteria). Category 12 (appropriate statistical analysis) was the most unfulfilled item, no power 
analysed or effect sizes were estimated. In category 9 (participants analysed in the original group) 
was rated as not applicable (N/A) in two of the included studies19,59 since their follow-up was 
complete, so the intention-to-treat analysis was not used in these cases. Randomization (Q1), 
identical group treatment (Q7), complete follow-up (Q8), outcomes measured (Q10), and trial 
design (Q13) were the best methodological standards. Methodological quality was better in those 
non-randomized studies (Table 3), all 18 studies met at least 5 (50%) of the defined appraisal 
criteria. Four31,40,41,50 of the 18 assessed articles met 7 or more (80%) of the 9 criteria of the JBI for 
QES. Categories 4 (presence of a control group) and 9 (appropriate statistical analysis) was the 
most unfulfilled item, no power analysed or effect sizes were estimated. A clear cause/effect (Q1), 
identical compared groups (Q2), pre- and post- measures (Q5), complete follow-up (Q6), and 









Table 2. Methodological quality assessment using The Joanna Briggs Institute Critical Appraisal Checklist for Randomized 
Clinical Trials. 
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Score (/13) 
Ancoli-Israel et al.54 Y U N U U N Y N N Y U N Y 4 
Ancoli-Israel et al.55 Y U N U N N Y N U Y Y N Y 5 
Ancoli-Israel et al.56 Y U N U N N Y Y U Y Y N Y 6 
Burns et al.51 Y U Y U U Y Y Y Y Y Y N Y 9 
Dowling et al.19 Y U Y N N N Y Y N/A Y U N Y 6 
Dowling et al.57 Y U Y N N N Y Y U Y U N Y 6 
Dowling et al.58 Y U Y N N N Y U U Y Y N Y 6 
Dowling et al.59 Y U N Y Y Y Y Y N/A Y U Y Y 9 
Fontana Gasio et al.49 Y U Y U U U U Y U Y U Y Y 6 
Friedman et al.33 Y U Y U U U Y Y U Y U N Y 6 
Graf et al.34 Y U U U U Y U Y U Y U N Y 5 
Haffmans et al.42 Y U U Y Y Y U Y U Y Y N Y 8 
Lyketsos et al.63 Y U Y U U Y Y Y Y Y U N Y 8 
McCurry et al.44 Y Y Y U U Y Y Y Y Y Y Y Y 11 
Onega et al.53 Y U Y Y N Y Y Y U Y Y Y Y 10 
Onega et al.67 Y U N Y N Y Y Y U Y Y N Y 9 
Riemersma van der Lek et al.30 Y Y N Y Y Y Y Y Y Y U Y Y 11 
Sloane et al.45 Y U U U U U U Y U Y U N Y 4 
Note: Q1: Randomization; Q2: Concealed allocation; Q3: Groups similar at baseline; Q4: Participants blinded; Q5: Allocator 
blinded; Q6: Assessors blinded; Q7: Groups treated equally; Q8: Follow-up complete; Q9: Participants analysed in original 
group; Q10: Outcomes measured in the same way in groups; Q11: Outcomes measured reliably; Q12: Appropriate statistical 
analysis; Q13: Appropriate trial design. Abbreviations: Y: Yes; N: No; U: Unclear; N/A: not applicable. 
 
Light therapy and BPSD 
Three studies35,39,52 analysing the effect of light therapy on BPSD as a whole found 
improvements on BPSD. Two of these35,52 showed a substantial reduction in the frequency of 
behaviour disorders, and in one of them,52 it was also reported a mean decrease of total disruptive 
behaviours during the light intervention. 
 
In the following subsections, our results are presented classified according to the effect of light 
therapy on specific BPSD: sleep, agitation, mood, and neuropsychiatric symptoms. 
 
Table 3. Methodological quality assessment using The Joanna Briggs Institute Critical Appraisal Checklist for Quasi-
Experimental Studies. 
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Score (/9) 
Barrick et al.31 Y Y U Y Y Y Y Y Y 8 
Fetveit et al.46 Y Y U N Y Y Y U N 5 
Fetveit and Bjorvatn47 Y Y U N Y Y Y Y N 6 
Fetveit and Bjorvatn48 Y Y U N Y Y Y Y N 6 
Figueiro et al.64 Y Y U N Y N Y Y N 5 
Figueiro et al.32 Y Y U N Y N Y Y Y 6 
Hickman et al.40 Y Y U Y Y Y Y Y Y 8 
Lovell et al.24 Y Y U N Y Y Y U N 5 
Mishima et al.35 Y N U Y Y Y Y Y N 6 
Mishima et al.36 Y N U N Y Y Y Y N 5 
Münch et al.50 Y Y U Y N Y Y Y Y 7 
Satlin et al.37 Y Y U N Y Y Y U N 5 
Schindler et al.29 Y Y U N Y Y Y U N 5 
Sekiguchi et al.38 Y Y U N Y Y Y U N 5 
Skjerve et al.39 Y Y U N Y Y Y U N 5 
Sloane et al.41 Y Y U Y Y Y Y Y Y 8 
Thorpe et al.52 Y Y U N Y Y Y Y N 6 
van Someren et al.43 Y Y U N Y Y Y U N 5 
Note: Q1: Clear cause and effect; Q2: Participants included in comparison similar; Q3: Any comparison other than 
intervention of interest; Q4: Control group; Q5: Multiple measurements pre and post-intervention; Q6: Follow-up 
complete; Q7: Outcomes measured in the same way in groups; Q8: Outcomes measured reliably; Q9: Appropriate 
statistical analysis. Abbreviations: Y: Yes; N: No; U: Unclear; N/A: not applicable. 
Light therapy and sleep 
Of the 25 articles assessing the effect of light therapy on sleep disorders, 19 utilized actigraphy. 
Actigraphy is a reliable technique to study the effect of treatments on sleep and circadian rhythm 
disorders in people with dementia.60 In addition to using actigraphy, six articles complemented 
the evaluation of sleep with subjective measures; three of them incorporated an own questionnaire 
of sleep-wakefulness disturbances,39,46,48 and the other three32,33,51 included daily sleep reports, plus 
the Pittsburgh Sleep Quality Index (PSQI)61 in one case32 and the Epworth Sleepiness Scale, 
ESS62 in another one.33 Other three articles35,37,63 only used daily ratings by nursing staff, two 
articles45,64 included only the PSQI, in one study the assessment was made by the Neuropsychiatric 
Inventory, Nursing Home version (NPI-NH)65 and finally, one article used the Sleep Disorders 
Inventory (SDI) .66 
 
Only three of the 25 articles reviewed33,45,50 found no significant improvement in sleep 
disturbances. Sekiguchi et al.38 found evidence only in 4 out of 17 patients, those with mild to 
moderate Alzheimer's disease and a shorter duration of illness. 
 
Light therapy and agitation 
Seven24,30,42,52,53,55,64 of the 12 articles evaluating the effect of light therapy on agitation 
provided significant evidence of potential beneficial effects on this symptom. Three37,50,63 found no 
significant improvement in behavioural symptoms in people with dementia, one51 reported only 
limited evidence of a reduction in agitation, and finally, in the study of Barrick et al.31 light 
therapy resulted in an exacerbation of agitation levels during treatment periods. 
 
Light therapy and mood 
Five out of 10 articles focused on evaluating the use of light therapy for improving mood found 
a significant decrease in depressive symptoms30,32,53,64,67 and another one found more positive 
emotions, with greater general alertness.50 Moreover, Hickman et al.40 found limited evidence 
since depressive symptomatology only decreased in some people with dementia, while other 
patients showed a worsening of such symptoms. The remaining three articles45,51,63 found no 
benefits of light therapy on mood. 
 
Light therapy and neuropsychiatric symptoms 
Three of the four articles that evaluate the impact of light therapy on neuropsychiatric 
symptoms (NPS) use the Neuropsychiatric Inventory, two of them49,58 use the Nursing Home 
version (NPI-NH)65 and the other one30 utilizes the questionnaire format.68 In two of these 
articles,30,49 no significant effects were found neither in the severity of the symptoms either in 
distress of the caregivers. Conversely, Dowling et al.58 found significant ameliorations in 
depression/dysphoria, aberrant motor behaviour, and appetite/eating disorders, but pointing out the 
low clinical meaning of the outcomes, with no clinical effect on the agitation/aggression of 
patients with dementia. The fourth of the articles29 on neuropsychiatric symptoms specifically 
addresses delusions and hallucinations in a small group of patients with Alzheimer's disease. These 
authors found contradictory results, during the intervention, three of the participants slightly 
improved the delusional symptoms that they presented before, and another participant did not 
show delusions neither before nor during the treatment. Conversely, one participant without 
previous delusional symptomatology developed paranoid delusions and visual hallucinations 
during the intervention, disappearing one day after the end of the treatment. 
 
Light therapy and cognition 
Only four studies were included in this review. Two of them30,34 found significant beneficial 
effects on cognition decline with increasing Mini-Mental State Examination (MMSE) de Folstein69 
total scores after light treatment. Nevertheless, other authors48,50 found no significant differences in 
MMSE scores after treatment, nor in the neuropsychological tests developed for the Consortium to 
Establish a Registry for Alzheimer's Disease (CERAD)70 for the measurement of memory, 
cognitive impairment and the progression of dementia.49 
  
Light therapy and quality of life 
Münch et al.50 reported better quality of life of severely demented patients after light exposure, 
with better scores using the Quality of Life for Severe Dementia instrument (QUALID).71 
However, a previous study45 reported no significant differences in Quality of Life in Alzheimer's 
Disease scores (QOL-AD) .72 
 
Light therapy and activities of daily living 
Two of the articles30,64 included in this review addressed, among others, the effect of light 
therapy on the functioning of the activities of the participant's daily life,. In one of these studies,64 
it was used the Minimum Data Set Activities of Daily Living Scale (MDS-ADL)73 to measure the 
dependence in the performance of activities of daily living (ADL), showing a decrease in the 
scores over time without significant differences. In the other study,30 it was found evidence that 




The characteristics of the intervention protocol varied among the studies regarding the type and 
intensity of the light as well as the duration and frequency of the intervention (see Table 1). In the 
majority of the articles included in this review, older adults with cognitive impairment were 
exposed to white bright light, with a high variability of light intensities consisting of doses ranging 
from 417.24 lux50 to 10,000 lux.51, 52, 53,63,67 The most repeated intensity value of the treatment 
light, appearing in eleven of the 36 selected articles, was a light intensity of 2500 lux,19,24,29,41,44,54, 
55, 56, 57, 58, 59 followed by the value of 10,000 lux, which was shown in 6 of the articles. On the 
other hand, four studies used a different type of light treatment. In three32,45,64 of them, participants 
were exposed to a bluish-white light as the treatment condition, and in the other one,49 it was used 
as a naturalistic form of light therapy called dawn-dusk simulation (DDS). 
 
With respect to the time of day, excluding McCurry et al.44 who provided evening bright light 
sessions, and Fontana Gasio et al.49 who used a special application that includes exposure at dawn 
and dusk time, all the articles included light intervention in the morning. Ten out of the 
articles31,40,41,53, 54, 55, 56, 57, 58,67 established experimental designs including both morning and 
evening bright light, with more significant effects in the morning sessions. Six of the 
studies30,32,43,45,50,64 reported a combined design, with bright light sessions from the time of 
awakening until 18:00. 
 
Diversity across the studies was also observed in terms of the frequency and duration of light 
therapy, ranging from 30 min33,42 to 8–10 h32,64 per day, with two hours per day being the most 
frequent intervention duration,24,29,34, 35, 36, 37,46, 47, 48,51,54, 55, 56 followed by one hour per day present 
in seven of the articles.19,38,44,57, 58, 59,63 Two of the studies31,40 included an experimental group that 
was exposed to all-day bright light from 7 a.m. to 8 p.m., but a longer exposure time to the lighting 
conditions did not demonstrate improved effects. There was also a variety in the light intervention 
duration, with a minimum of 5 days52 and a maximum of 15±12 months.30 The most common 
duration of light treatment were periods time of two weeks29,33,37,38,46, 47, 48,51 and four 
weeks,32,35,36,39,42,43,63,64 each period being used respectively in eight of the articles analysed. 
Table 4 includes the most repeated characteristics of light therapy used only in the studies with 
positive results in any of their outcomes measures. 
Table 4. The most repeated characteristics of light therapy in the included studies providing positive results. 
Intervention characteristics 
Type of light Intensity  Time of day Frequency (time/day)  Total duration 
White bright light 2500–10,000 lx Morning  30 min–2 h  2–4 weeks 
Discussion 
This systematic review aimed to analyse studies exploring light therapy in people with 
cognitive impairment to assess its efficacy as a non-pharmacological approach to manage BPSD, 
cognition, functional status and quality of life. The current review provides potential evidence that 
light therapy has positive effects on BPSD, but limited evidence of its effectiveness on cognition, 
quality of life and functioning in activities of daily living. The secondary objective was to identify 
the light therapy conditions with the highest benefits for older adults with cognitive impairment, 
seeking to define guidelines for an adequate protocol in order to facilitate its clinical application 
with this population. There were great differences between the characteristics of the intervention 
protocols of the analysed studies, so we synthetized the conditions most commonly used in those 
studies with positive results. 
 
The articles analysed yielded findings of positive effects of light therapy on BPSD in people 
with dementia. There is numerous research addressing the effects of light therapy on this 
symptomatology, especially regarding sleep, agitation and mood. 
 
Most of the publications focus on sleep, reporting significant improvements after or during the 
intervention, except from four out of the 25 included articles, which found ameliorations only in 
some of the participants38 or no significant changes in sleep disturbances.33,45,50 Additionally, 
better effects on rest-activity rhythms were observed in older people with vascular dementia than 
those with dementia of Alzheimer's type, probably due to the higher desynchronization of the 
circadian rhythm in those with vascular dementia.36 
 
The second most reported symptom is agitation, with the majority of the publications analysed 
showing a reduction in it after the intervention with light therapy. Bright light therapy improved 
agitation symptoms, with a significant decrease in caregiver ratings of physical, verbal and total 
agitation measured with the Cohen-Mansfield Agitation Inventory (CMAI)74 from baseline to the 
end of the treatment, delaying acrophase of the agitation rhythm; however, it had little effect on 
observational ratings of agitation.55 These authors also concluded that this therapy is more 
adequate in older people with milder forms of dementia since those with severe dementia possess 
an SCN that is too degenerated to benefit from light treatment. In contrast to this study, Skjerve et 
al.39 showed improved behavioural symptoms in people with severe dementia, also suggesting a 
delay in activity rhythms. Other authors30,52,64 also used the CMAI for the measurement of agitated 
behaviours, showing a significant decrease of agitation; in one of these articles,30 the positive 
effects were found only in the condition of light exposure combined with melatonin 
administration. Additionally, in another study,42 bright light therapy showed a positive effect on 
motor restless behaviour after treatment, with patients being less restless and more cooperative. A 
potential effect, albeit with limited evidence, was also observed for agitation in severely 
cognitively impaired patients.51 Light therapy is a treatment that may be used at home to reduce 
agitation.24 The effectiveness of light therapy to reduce agitation (with significant effects on four 
measures of agitation) provides a non-pharmacological alternative to pharmacological treatment,53 
in which serious side effects are uncommon.39 In contrast to this effect of light therapy, other 
authors31 even observed a worsening of behavioural symptoms. Nevertheless, this study includes 
among its limitations that those patients who responded favourably to the light treatment were 
discharged because of their decreased agitation level. Lyketsos et al.63 explain the lack of effect on 
agitation due to the use of a short-term intervention (4 weeks) or to the absence of a sleep/wake 
cycle disorder in their study sample. These different outcomes are in conjunction with the different 
instruments used to measure agitation, the different levels of dementia severity of the patients or 
the lack of controlling important parameters, as medication consumption or changes before and 
during the light intervention, among the studies. 
 
Regarding mood, six out of ten articles showed an improvement in depressive 
symptomatology. In one of these articles,67 the effect of light therapy was compared between two 
groups of participants assigned to them based on their stage of dementia (mild to moderate 
dementia vs severe dementia). Both groups showed an improvement in total scores, but differences 
in two subscales of the Depressive Symptom Assessment for Older Adults (DSAOA),75 where 
patients at severe stages of dementia showed greater benefits of the intervention. As opposed to 
these results, no positive effect of light therapy on mood was found in three articles.45,51,63 
Moreover, Hickman et al.40 found positive effects in some of the participants after the light therapy 
intervention, but conversely other participants showed a worsening of their depressive symptoms. 
Circadian disruption increases the likelihood of depressive symptoms, which are also linked to the 
sleep disturbances76 since alterations of rest-activity rhythm contribute to depressive episodes.77 
Light treatment is also a non-pharmacological option to reduce depression and depressive 
symptomatology in older adults with dementia,53 although the magnitude of the effect may not 
always be clinically significant.58 This effect is large if the efficacy of bright light therapy on 
depressive symptoms is studied in people with depression or depressive symptomatology at 
baseline.40 These findings are not consistent with those of Burns et al.50 who showed no significant 
differences in Cornell scores,78 or those of Lyketsos et al.63 who reported no significant changes 
after bright light exposure in people with dementia. Differences between the methods used to 
measure depressive symptoms in people with dementia or the collection of information from the 
caregivers also influence outcomes on the effect of the lighting intervention.40 
 
The BPSD with the least research is the neuropsychiatric symptoms, having found only four 
articles to include in the current review. Three of the articles30,49,50 evaluated the impact of light 
therapy on general NPS, with significant improvements in only one of them.58 The fourth article 
was focus on delusional symptomatology, finding conflicting results among participants of the 
study: three slightly improved, one showed no change, and another participant began to experience 
hallucinations and delusions during the intervention.29 There is a lack of research regarding the 
effects of light therapy on psychotic symptoms associated with dementia. Taguchi et al.79 
examined the use of bright light therapy as a prevention tool of postoperative delirium in a sample 
of middle-aged and aged hospitalized patients. These authors found that the hallucinations 
disappeared at the first or second day of the intervention in the experimental group, but they 
persisted in the control group for several days. Therefore, bright light therapy seems to be useful in 
the management of NPS, but its application requires caution, as it has been suggested that it may 
have a significant impact on the onset of delusional symptomology in the course of Alzheimer's 
disease.29 
 
Respecting cognition, we found limited and conflicting evidence for the effects of light 
therapy. In two of the articles analysed,30,34 participants showed an increase in MMSE total scores 
after the intervention, by contrast in the other two studies,48,50 no significant changes were shown 
in either the MMSE or CERAD scores. Importantly, neuroimaging studies have shown that light 
regulates cognitive brain activity, which affects cognition and alertness, contributing to sleep and 




Although the direct effect on the quality of life is not usually considered in the studied articles 
and is even controversial, improvement of sleep disturbances would also indirectly improve the 
quality of life of people with dementia.76 Thus, increased light exposure is associated with 
significant differences in quality of life in older community-dwelling people.81 
 
Likewise, research on the impact of light therapy on functional status in people with cognitive 
impairment is also scarce, having found for this review only two articles on this topic. The existing 
studies30,64 showed potential benefits of light therapy on the functioning of the participants in their 
activities of daily living. It is important to promote future research addressing the effects of light 
therapy on functional status due to its high importance in the field of gerontology and geriatrics. 
 
Finally, regarding the intervention characteristics, it was found high heterogeneity among the 
protocols of the studies included in the current review. This lack of homogeneity can affect the 
different outcomes found in the analysed articles. In general, including all the literature addressed, 
treatment sessions can last from 30 min to 13 h depending on the equipment used, dosing 2500–
10,000 lux, once or twice a day, for a total intervention period time ranging from 10 days to 10 
weeks. With the purpose of providing guidelines for future research in this area, as observed in 
Table 4, we synthetized the most used characteristics among the studies that resulted in positive 
effects on the outcome measures. Lastly, the application of light therapy does not require a 
prescription, but it is important that clinical staff who are familiar with this intervention explain 
and supervise its application both in institutions and at home. Likewise, although contraindications 
for light therapy are few,82 following up once the intervention has begun is essential to control 
changes, paying particular attention to the development or increase of neuropsychiatric 
symptoms,29 making adjustments to the intervention protocol if necessary. 
Strengths and limitations 
This review should be understood considering some limitations. First, the limited number of 
people participating in some studies and the heterogeneity of the methodological aspects for light 
intervention can affect the robustness and clinical relevance of some of the described outcomes 
and conclusions. In contrast, we carry out an evaluation of the methodological quality for each 
included study in order to strengthen our results. Additionally, the main strength of this review is 
the absence of a limit on search years. In addition, we required validated instruments criteria to 
analyse the effect on BPSD, quality of life and cognitive status in older people, and we presented 
well-defined aims and explicit inclusion criteria. Besides, we pursued to know the effect of light 
therapy in older adults (aged 65 years or older) with cognitive impairment, having or no having 
dementia diagnosis. 
Conclusions 
This systematic review showed potential evidence for positive effects of light therapy on 
managing sleep, behavioural and mood disturbances in people with cognitive impairment, but 
more research is needed to support these results. A limited effect was found respecting cognition, 
quality of life and functional status. Despite the great heterogeneity found in the studies, this 
review reported the most commonly repeated parameters of light therapy used in older adults with 
cognitive impairment with positive results throughout the literature, thus offering a guide for the 
design of future studies in this field. Therefore, future studies should be designed to determine the 
optimal intensity, frequency and duration of the intervention as well to assess its effectiveness. 
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